Compare Quest Diagnostics Inc (DGX) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Marriott International Inc — how do they compare? Quest Diagnostics Inc trades at $237.49 (market cap $26.21B), while Marriott International Inc trades at $355.23 (market cap $91.14B). The key difference: Marriott International Inc is far larger — about 3.5× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | MAR | |
|---|---|---|
Market Cap | $26.21B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $402.54 |
52-Week Low | $173.49 | $259.04 |
Enterprise Value | $31.97B | $108.45B |
Dividend Yield | 1.45% | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Marriott International (MAR) trades at $356.31, up 2.26% today, with a bearish technical signal from moving averages. Recent Q2 2026 earnings beat estimates with EPS of $3.19 versus $3.08 expected, driven by strong fee revenue growth. The company raised its 2026 outlook, supported by a record pipeline and AI-powered booking tools, though valuation remains elevated with a P/E of 36.18.
Outlook is mixed: analyst consensus targets $387.31 (8.7% upside) with 44% buy ratings, but high debt and Middle East weakness pose risks. The stock offers growth via fee-based model and dividends, but requires monitoring of RevPAR trends and macroeconomic pressures for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
